Healthpeak Properties (NYSE:DOC) Given New $21.50 Price Target at UBS Group

Healthpeak Properties (NYSE:DOC) had its price target boosted by analysts at UBS Group from $19.00 to $21.50 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the real estate investment trust’s stock. UBS Group’s price target would indicate a potential downside of 0.67% from the company’s current price.

A number of other equities research analysts also recently commented on the stock. BMO Capital Markets raised their price objective on shares of Healthpeak Properties from $20.00 to $24.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Scotiabank increased their target price on Healthpeak Properties from $19.00 to $21.00 and gave the stock a “sector perform” rating in a research note on Wednesday, May 27th. Evercore downgraded Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 price target on the stock. in a research note on Monday, May 11th. Raymond James Financial started coverage on Healthpeak Properties in a report on Wednesday, June 17th. They set a “market perform” rating on the stock. Finally, Robert W. Baird raised their target price on Healthpeak Properties from $19.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Four research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.50.

Healthpeak Properties Stock Performance

DOC traded down $0.28 on Wednesday, reaching $21.64. The company had a trading volume of 2,513,446 shares, compared to its average volume of 8,987,386. The company has a quick ratio of 2.96, a current ratio of 2.96 and a debt-to-equity ratio of 1.15. Healthpeak Properties has a 1 year low of $15.70 and a 1 year high of $22.13. The stock has a market capitalization of $14.92 billion, a PE ratio of 67.76, a P/E/G ratio of 3.39 and a beta of 1.02. The stock has a 50-day moving average price of $19.76 and a 200-day moving average price of $17.93.

Healthpeak Properties (NYSE:DOC) last posted its quarterly earnings data on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The business had revenue of $752.95 million during the quarter, compared to the consensus estimate of $694.59 million. During the same period in the prior year, the company earned $0.46 earnings per share. The company’s revenue was up 7.1% compared to the same quarter last year. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. As a group, research analysts forecast that Healthpeak Properties will post 1.75 EPS for the current fiscal year.

Insider Activity

In related news, insider Scott R. Bohn sold 10,989 shares of Healthpeak Properties stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the transaction, the insider directly owned 7,636 shares in the company, valued at $148,520.20. The trade was a 59.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.23% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Healthpeak Properties

Hedge funds have recently bought and sold shares of the stock. State Street Corp lifted its position in shares of Healthpeak Properties by 1.8% in the third quarter. State Street Corp now owns 49,498,109 shares of the real estate investment trust’s stock valued at $947,889,000 after acquiring an additional 895,460 shares in the last quarter. JPMorgan Chase & Co. increased its position in Healthpeak Properties by 8.6% during the 4th quarter. JPMorgan Chase & Co. now owns 30,674,812 shares of the real estate investment trust’s stock worth $493,251,000 after purchasing an additional 2,438,278 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in Healthpeak Properties by 19.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust’s stock valued at $476,744,000 after purchasing an additional 4,776,056 shares during the last quarter. Geode Capital Management LLC raised its stake in Healthpeak Properties by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 19,534,041 shares of the real estate investment trust’s stock valued at $312,959,000 after purchasing an additional 123,274 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in Healthpeak Properties by 9.9% in the 4th quarter. Invesco Ltd. now owns 18,298,776 shares of the real estate investment trust’s stock valued at $294,244,000 after purchasing an additional 1,648,012 shares in the last quarter. Hedge funds and other institutional investors own 93.57% of the company’s stock.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.